The Global Health Innovative Technology (GHIT) Fund has secured a pledge from the Bill & Melinda Gates Foundation of $24 million (approximately JPY 3.2 billion) over three years for GHIT Fund's third five-year plan, GHIT 3.0 (from FY2023 to FY2027).

Since its inception in 2013, the GHIT Fund has been investing in new product development and committed to portfolio management to contribute to global health, supporting Japanese technology and innovation to combat infectious diseases, such as malaria, tuberculosis and neglected tropical diseases (NTDs), which affect the world's vulnerable and underserved populations.

In April 2023, the 10^th anniversary of its founding, GHIT has put the aim to streamline and accelerate research and development for malaria, tuberculosis, NTDs and other infectious diseases. 

As of March 30, 2023, there are 53 ongoing projects, including 26 discovery, 15 preclinical and 12 clinical trials in the GHIT portfolio. The total amount invested since 2013 is JPY 29.1 billion (approx. $217 million). The GHIT Fund has 170 partners (59 domestic and 111 overseas) that have participated in product development to date, and the number of Japanese and overseas institutions has dramatically increased over the past 10 years.

The GHIT Fund is a Japan-based international public-private partnership fund (PPP) that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP).